Hospital
Greater Regional Medical Center
Greater Regional Medical Center was paid $10.02M by Medicaid between Jan 2018 and Dec 2024, across 144 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoGREATER REGIONAL MEDICAL CENTER
CRESTON, IA 50801
CRESTON, IA 50801
33aNPI1902805062assigned 07/20/2005
33bProvider typeCritical Access Hospital
28Total paid$10.02M
24GClaims238,288
24DCodes billed144
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Iowa
Rank by total paid#1 of 79
Median peer was paid$801K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,506 | $1.23M | |
| 2019 | 36,330 | $1.22M | |
| 2020 | 29,803 | $1.23M | |
| 2021 | 36,178 | $1.64M | |
| 2022 | 38,697 | $1.82M | |
| 2023 | 33,961 | $1.63M | |
| 2024incomplete | 25,813 | $1.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 11,863 | 8,893 | $2.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 13,507 | 9,957 | $2.16M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 54,619 | 50,288 | $1.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 2,488 | 2,061 | $675K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.8% | 46,729 | 41,941 | $479K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.6% | 9,458 | 8,679 | $358K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 7,100 | 6,289 | $279K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.1% | 15,770 | 14,252 | $213K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,685 | 3,300 | $161K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 9,600 | 8,423 | $159K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 896 | 821 | $96K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,219 | 1,133 | $89K |
132 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,817 | $87K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,567 | $84K |
| 80053 | Comprehensive metabolic panel | <1% | 1,406 | $66K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,450 | $66K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 669 | $62K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,704 | $61K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,566 | $54K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,201 | $49K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 738 | $48K |
| 84484 | <1% | 908 | $43K | |
| 80047 | <1% | 3,055 | $41K | |
| 86140 | <1% | 1,008 | $41K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,137 | $41K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,644 | $37K |
| A0425 | Ground mileage, per statute mile | <1% | 414 | $37K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,642 | $36K |
| 71045 | Radiologic examination, chest; single view | <1% | 575 | $32K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 586 | $32K |
| 83605 | <1% | 499 | $31K | |
| 84145 | <1% | 692 | $31K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 953 | $28K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 550 | $28K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,874 | $25K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 56 | $25K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 419 | $23K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 470 | $22K |
| 81001 | <1% | 919 | $22K | |
| 92567 | <1% | 1,314 | $20K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 22 | $19K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,177 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 449 | $18K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 584 | $17K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 68 | $14K |
| 81003 | <1% | 821 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 354 | $11K |
| 90473 | <1% | 743 | $11K | |
| 86141 | <1% | 681 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 156 | $10K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 282 | $9K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 194 | $9K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 598 | $9K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $8K |
| 85027 | <1% | 555 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 516 | $8K |
| 81002 | <1% | 810 | $7K | |
| 87486 | <1% | 215 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 168 | $6K |
| 90461 | <1% | 319 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 168 | $5K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 215 | $5K |
| 81025 | <1% | 279 | $5K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 405 | $5K |
| 87581 | <1% | 215 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 201 | $4K |
| 73630 | <1% | 147 | $4K | |
| 80061 | Lipid panel | <1% | 131 | $4K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 18 | $4K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 49 | $3K |
| 87070 | <1% | 182 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 89 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 63 | $3K |
| 90688 | <1% | 250 | $3K | |
| 59025 | Fetal non-stress test | <1% | 33 | $3K |
| 84439 | <1% | 181 | $3K | |
| 87088 | <1% | 191 | $2K | |
| 92557 | <1% | 88 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 56 | $2K |
| 80076 | <1% | 42 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 74 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 83 | $2K |
| 11720 | <1% | 334 | $2K | |
| 87634 | <1% | 27 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 59 | $2K |
| 82728 | <1% | 55 | $2K | |
| 82077 | <1% | 17 | $2K | |
| 80305 | <1% | 74 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 68 | $1K |
| 86780 | <1% | 26 | $1K | |
| 83690 | <1% | 29 | $1K | |
| 91322 | <1% | 19 | $1K | |
| 87807 | <1% | 111 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 17 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $1K |
| 86850 | <1% | 16 | $1K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 41 | $930.78 |
| 90686 | <1% | 1,533 | $793.75 | |
| 73562 | <1% | 87 | $768.03 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14 | $737.80 |
| 99441 | <1% | 77 | $686.28 | |
| 80143 | <1% | 13 | $650.60 | |
| 87631 | <1% | 12 | $591.43 | |
| 82553 | <1% | 17 | $561.93 | |
| 80179 | <1% | 12 | $552.51 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 18 | $529.10 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $438.79 |
| 90620 | <1% | 50 | $428.22 | |
| 90715 | <1% | 160 | $403.82 | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $375.46 |
| 90651 | <1% | 261 | $364.92 | |
| 85007 | <1% | 19 | $329.09 | |
| 86803 | <1% | 12 | $302.40 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 85 | $294.87 |
| A9270 | Non-covered item or service | <1% | 127 | $280.28 |
| 86900 | <1% | 16 | $220.18 | |
| 90734 | <1% | 303 | $218.54 | |
| 86901 | <1% | 16 | $215.69 | |
| 99497 | <1% | 17 | $185.08 | |
| 99442 | <1% | 13 | $151.33 | |
| 90656 | <1% | 118 | $131.72 | |
| 72100 | <1% | 13 | $130.86 | |
| G0008 | Administration of influenza virus vaccine | <1% | 45 | $126.48 |
| 73030 | <1% | 13 | $114.59 | |
| 73130 | <1% | 17 | $101.28 | |
| 85018 | <1% | 12 | $76.56 | |
| 90633 | <1% | 774 | $61.89 | |
| 99318 | <1% | 32 | $59.58 | |
| 90480 | <1% | 19 | $51.42 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 342 | $2.00 |
| 90670 | <1% | 1,270 | $0.49 | |
| 90647 | <1% | 782 | $0.35 | |
| 90723 | <1% | 932 | $0.29 | |
| 90680 | <1% | 631 | $0.23 | |
| 90685 | <1% | 184 | $0.17 | |
| 90696 | <1% | 60 | $0.05 | |
| 90648 | <1% | 213 | $0.05 | |
| 90710 | <1% | 48 | $0.04 | |
| 90700 | <1% | 38 | $0.03 | |
| 90716 | <1% | 59 | $0.01 | |
| 90707 | <1% | 48 | $0.01 | |
| 90697 | 0% | 12 | $0.00 | |
| 90681 | 0% | 123 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCUTCHAN, MATT (CFO)